Moloney Securities Asset Management’s Revolution Medicines RVMD Stock Holding History

Moloney Securities Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,650	Closed	-$252K	–	448
2023 Q1	$252K	Sell	11,650 -9,500	-45%	-$234K	0.05%	348
2022 Q4	$504K	Sell	21,150 -4,500	-18%	-$95.7K	0.11%	217
2022 Q3	$506K	Sell	25,650 -14,250	-36%	-$313K	0.12%	202
2022 Q2	$778K	Buy	+39,900	New	+$777K	0.18%	150
2021 Q2	–	Sell	-4,500	Closed	-$206K	–	452
2021 Q1	$206K	Sell	4,500 -2,050	-31%	-$91.9K	0.04%	374
2020 Q4	$259K	Sell	6,550 -500	-7%	-$19.8K	0.06%	315
2020 Q3	$245K	Buy	+7,050	New	+$195K	0.06%	274

Other funds holding RVMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Moloney Securities Asset Management's RVMD Position: Q2 2023 in Review

Moloney Securities Asset Management sold out of Revolution Medicines (RVMD) in Q2 2023, closing a stake of 11,650 shares — an estimated $252K sold.

Moloney Securities Asset Management first reported a position in RVMD in Q3 2020 and held it in 7 quarters. The position peaked at $778K in Q2 2022. 139 funds tracked by Wall St. Rank hold RVMD as of Q2 2023.

Moloney Securities Asset Management reported no remaining Revolution Medicines position as of Q2 2023 after selling out during the quarter.
Moloney Securities Asset Management sold 11,650 Revolution Medicines shares in Q2 2023, an estimated $252K.
Moloney Securities Asset Management first reported a position in Revolution Medicines in Q3 2020 and held it in 7 quarters.
Moloney Securities Asset Management's Revolution Medicines position peaked at $778K in Q2 2022.
139 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2023.

Based on Moloney Securities Asset Management's 13F filing for Q2 2023, filed 31 Jul 2023.